Cargando…

Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery

Alzheimer’s disease (AD) is the most common cause of dementia, characterized by progressive cognitive decline and neurodegenerative disorder. Abnormal aggregations of intracellular neurofibrillary tangles (NFTs) and unusual accumulations of extracellular amyloid-β (Aβ) peptides are two important pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Shan-Ju, Chung, Ming-Hsun, Chen, Bor-Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540696/
https://www.ncbi.nlm.nih.gov/pubmed/34681938
http://dx.doi.org/10.3390/ijms222011280
_version_ 1784589049507348480
author Yeh, Shan-Ju
Chung, Ming-Hsun
Chen, Bor-Sen
author_facet Yeh, Shan-Ju
Chung, Ming-Hsun
Chen, Bor-Sen
author_sort Yeh, Shan-Ju
collection PubMed
description Alzheimer’s disease (AD) is the most common cause of dementia, characterized by progressive cognitive decline and neurodegenerative disorder. Abnormal aggregations of intracellular neurofibrillary tangles (NFTs) and unusual accumulations of extracellular amyloid-β (Aβ) peptides are two important pathological features in AD brains. However, in spite of large-scale clinical studies and computational simulations, the molecular mechanisms of AD development and progression are still unclear. In this study, we divided all of the samples into two groups: early stage (Braak score I–III) and later stage (Braak score IV–VI). By big database mining, the candidate genetic and epigenetic networks (GEN) have been constructed. In order to find out the real GENs for two stages of AD, we performed systems identification and system order detection scheme to prune false positives with the help of corresponding microarray data. Applying the principal network projection (PNP) method, core GENs were extracted from real GENs based on the projection values. By the annotation of KEGG pathway, we could obtain core pathways from core GENs and investigate pathogenetic mechanisms for the early and later stage of AD, respectively. Consequently, according to pathogenetic mechanisms, several potential biomarkers are identified as drug targets for multiple-molecule drug design in the treatment of AD.
format Online
Article
Text
id pubmed-8540696
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85406962021-10-24 Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery Yeh, Shan-Ju Chung, Ming-Hsun Chen, Bor-Sen Int J Mol Sci Article Alzheimer’s disease (AD) is the most common cause of dementia, characterized by progressive cognitive decline and neurodegenerative disorder. Abnormal aggregations of intracellular neurofibrillary tangles (NFTs) and unusual accumulations of extracellular amyloid-β (Aβ) peptides are two important pathological features in AD brains. However, in spite of large-scale clinical studies and computational simulations, the molecular mechanisms of AD development and progression are still unclear. In this study, we divided all of the samples into two groups: early stage (Braak score I–III) and later stage (Braak score IV–VI). By big database mining, the candidate genetic and epigenetic networks (GEN) have been constructed. In order to find out the real GENs for two stages of AD, we performed systems identification and system order detection scheme to prune false positives with the help of corresponding microarray data. Applying the principal network projection (PNP) method, core GENs were extracted from real GENs based on the projection values. By the annotation of KEGG pathway, we could obtain core pathways from core GENs and investigate pathogenetic mechanisms for the early and later stage of AD, respectively. Consequently, according to pathogenetic mechanisms, several potential biomarkers are identified as drug targets for multiple-molecule drug design in the treatment of AD. MDPI 2021-10-19 /pmc/articles/PMC8540696/ /pubmed/34681938 http://dx.doi.org/10.3390/ijms222011280 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yeh, Shan-Ju
Chung, Ming-Hsun
Chen, Bor-Sen
Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery
title Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery
title_full Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery
title_fullStr Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery
title_full_unstemmed Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery
title_short Investigating Pathogenetic Mechanisms of Alzheimer’s Disease by Systems Biology Approaches for Drug Discovery
title_sort investigating pathogenetic mechanisms of alzheimer’s disease by systems biology approaches for drug discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540696/
https://www.ncbi.nlm.nih.gov/pubmed/34681938
http://dx.doi.org/10.3390/ijms222011280
work_keys_str_mv AT yehshanju investigatingpathogeneticmechanismsofalzheimersdiseasebysystemsbiologyapproachesfordrugdiscovery
AT chungminghsun investigatingpathogeneticmechanismsofalzheimersdiseasebysystemsbiologyapproachesfordrugdiscovery
AT chenborsen investigatingpathogeneticmechanismsofalzheimersdiseasebysystemsbiologyapproachesfordrugdiscovery